Conditions:   Acute Lymphocytic Leukemia;   Acute Myelogenous Leukemia;   Burkitt's Lymphoma;   Follicular Lymphoma;   Hodgkin Lymphoma;   Mantle Cell Lymphoma
Interventions:   Drug: Biological/Vaccine: Haploidentical BMT;   Drug: Double Cord Blood Transplantation
Sponsors:   National Heart, Lung, and Blood Institute (NHLBI);   National Heart, Lung, and Blood Institute (NHLBI);   National Cancer Institute (NCI);   Blood and Marrow Transplant Clinical Trials Network
Not yet recruiting - verified May 2012

Conditions:   Leukemia;   Acute Myeloid Leukemia;   Acute Lymphocytic Leukemia;   Chronic Myeloid Leukemia;   Chronic Lymphocytic Leukemia;   Myeloproliferative Diseases;   Non-Hodgkins Lymphoma;   Hodgkins Lymphoma;   Multiple Myeloma;   Myelodysplastic Syndrome
Interventions:   Drug: Fludarabine monophosphate;   Drug: Busulfan;   Procedure: Stem Cell Infusion;   Drug: Tacrolimus;   Drug: Methotrexate;   Drug: G-CSF
Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center
Recruiting - verified April 2012

Condition:   Crohn's Disease
Interventions:   Drug: cyclophosphamide;   Radiation: total-body irradiation;   Drug: mycophenolic acid enteric coated;   Drug: tacrolimus;   Other: quality-of-life assessment;   Other: laboratory biomarker analysis;   Drug: fludarabine phosphate;   Procedure: allogeneic bone marrow transplantation
Sponsors:   Fred Hutchinson Cancer Research Center;   Fred Hutchinson Cancer Research Center
Not yet recruiting - verified April 2012

Condition:   Sickle Cell Disease
Intervention:   Other: Biological: Bone Marrow Transplant
Sponsors:   University of Pittsburgh;   University of Pittsburgh;   National Institutes of Health (NIH);   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified April 2012

Conditions:   Accelerated Phase Chronic Myelogenous Leukemia;   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Grade III Lymphomatoid Granulomatosis;   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative;   Blastic Phase Chronic Myelogenous Leukemia;   Chronic Eosinophilic Leukemia;   Chronic Myelomonocytic Leukemia;   Chronic Neutrophilic Leukemia;   Chronic Phase Chronic Myelogenous Leukemia;   Contiguous Stage II Adult Burkitt Lymphoma;   Contiguous Stage II Adult Diffuse Large Cell Lymphoma;   Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma;   Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma;   Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma;   Contiguous Stage II Adult Lymphoblastic Lymphoma;   Contiguous Stage II Grade 1 Follicular Lymphoma;   Contiguous Stage II Grade 2 Follicular Lymphoma;   Contiguous Stage II Grade 3 Follicular Lymphoma;   Contiguous Stage II Mantle Cell Lymphoma;   Contiguous Stage II Marginal Zone Lymphoma;   Contiguous Stage II Small Lymphocytic Lymphoma;   Cutaneous B-cell Non-Hodgkin Lymphoma;   de Novo Myelodysplastic Syndromes;   Essential Thrombocythemia;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Hepatosplenic T-cell Lymphoma;   Intraocular Lymphoma;   Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable;   Nodal Marginal Zone B-cell Lymphoma;   Noncontiguous Stage II Adult Burkitt Lymphoma;   Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma;   Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma;   Noncontiguous Stage II Adult Lymphoblastic Lymphoma;   Noncontiguous Stage II Grade 1 Follicular Lymphoma;   Noncontiguous Stage II Grade 2 Follicular Lymphoma;   Noncontiguous Stage II Grade 3 Follicular Lymphoma;   Noncontiguous Stage II Mantle Cell Lymphoma;   Noncontiguous Stage II Marginal Zone Lymphoma;   Noncontiguous Stage II Small Lymphocytic Lymphoma;   Noncutaneous Extranodal Lymphoma;   Peripheral T-cell Lymphoma;   Polycythemia Vera;   Previously Treated Myelodysplastic Syndromes;   Primary Myelofibrosis;   Progressive Hairy Cell Leukemia, Initial Treatment;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Adult T-cell Leukemia/Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Hairy Cell Leukemia;   Refractory Multiple Myeloma;   Relapsing Chronic Myelogenous Leukemia;   Secondary Acute Myeloid Leukemia;   Secondary Myelodysplastic Syndromes;   Secondary Myelofibrosis;   Small Intestine Lymphoma;   Splenic Marginal Zone Lymphoma;   Stage I Adult Burkitt Lymphoma;   Stage I Adult Diffuse Large Cell Lymphoma;   Stage I Adult Diffuse Mixed Cell Lymphoma;   Stage I Adult Diffuse Small Cleaved Cell Lymphoma;   Stage I Adult Hodgkin Lymphoma;   Stage I Adult Immunoblastic Large Cell Lymphoma;   Stage I Adult Lymphoblastic Lymphoma;   Stage I Adult T-cell Leukemia/Lymphoma;   Stage I Chronic Lymphocytic Leukemia;   Stage I Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage I Grade 1 Follicular Lymphoma;   Stage I Grade 2 Follicular Lymphoma;   Stage I Grade 3 Follicular Lymphoma;   Stage I Mantle Cell Lymphoma;   Stage I Marginal Zone Lymphoma;   Stage I Multiple Myeloma;   Stage I Mycosis Fungoides/Sezary Syndrome;   Stage I Small Lymphocytic Lymphoma;   Stage II Adult Hodgkin Lymphoma;   Stage II Adult T-cell Leukemia/Lymphoma;   Stage II Chronic Lymphocytic Leukemia;   Stage II Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage II Multiple Myeloma;   Stage II Mycosis Fungoides/Sezary Syndrome;   Stage III Adult Burkitt Lymphoma;   Stage III Adult Diffuse Large Cell Lymphoma;   Stage III Adult Diffuse Mixed Cell Lymphoma;   Stage III Adult Diffuse Small Cleaved Cell Lymphoma;   Stage III Adult Hodgkin Lymphoma;   Stage III Adult Immunoblastic Large Cell Lymphoma;   Stage III Adult Lymphoblastic Lymphoma;   Stage III Adult T-cell Leukemia/Lymphoma;   Stage III Chronic Lymphocytic Leukemia;   Stage III Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage III Grade 1 Follicular Lymphoma;   Stage III Grade 2 Follicular Lymphoma;   Stage III Grade 3 Follicular Lymphoma;   Stage III Mantle Cell Lymphoma;   Stage III Marginal Zone Lymphoma;   Stage III Multiple Myeloma;   Stage III Mycosis Fungoides/Sezary Syndrome;   Stage III Small Lymphocytic Lymphoma;   Stage IV Adult Burkitt Lymphoma;   Stage IV Adult Diffuse Large Cell Lymphoma;   Stage IV Adult Diffuse Mixed Cell Lymphoma;   Stage IV Adult Diffuse Small Cleaved Cell Lymphoma;   Stage IV Adult Hodgkin Lymphoma;   Stage IV Adult Immunoblastic Large Cell Lymphoma;   Stage IV Adult Lymphoblastic Lymphoma;   Stage IV Adult T-cell Leukemia/Lymphoma;   Stage IV Chronic Lymphocytic Leukemia;   Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage IV Grade 1 Follicular Lymphoma;   Stage IV Grade 2 Follicular Lymphoma;   Stage IV Grade 3 Follicular Lymphoma;   Stage IV Mantle Cell Lymphoma;   Stage IV Marginal Zone Lymphoma;   Stage IV Mycosis Fungoides/Sezary Syndrome;   Stage IV Small Lymphocytic Lymphoma;   T-cell Large Granular Lymphocyte Leukemia;   Testicular Lymphoma;   Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Adult Acute Myeloid Leukemia;   Untreated Hairy Cell Leukemia;   Waldenstrom Macroglobulinemia
Interventions:   Drug: sirolimus;   Drug: tacrolimus;   Biological: rituximab;   Biological: anti-thymocyte globulin;   Other: laboratory biomarker analysis;   Other: flow cytometry
Sponsors:   Barbara Ann Karmanos Cancer Institute;   Barbara Ann Karmanos Cancer Institute;   National Cancer Institute (NCI)
Recruiting - verified October 2011

Conditions:   Refractory Multiple Myeloma;   Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
Interventions:   Other: pharmacological study;   Drug: tacrolimus;   Drug: sirolimus;   Biological: anti-thymocyte globulin;   Drug: fludarabine phosphate;   Drug: busulfan;   Drug: bortezomib;   Procedure: allogeneic hematopoietic stem cell transplantation;   Other: laboratory biomarker analysis
Sponsors:   Barbara Ann Karmanos Cancer Institute;   Barbara Ann Karmanos Cancer Institute;   National Cancer Institute (NCI)
Recruiting - verified March 2012

Condition:   Medication Adherence
Intervention:   Device: Vitality GlowCaps
Sponsors:   University of Pennsylvania;   University of Pennsylvania;   Leonard Davis Institute, University of Pennsylvania;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified February 2012

Conditions:   Hematologic Malignancy;   Leukemia;   Acute Lymphoblastic Leukemia;   ALL;   Acute Myelogenous Leukemia;   AML;   Chronic Lymphocytic Leukemia;   CLL;   Lymphoma;   Hodgkin's Lymphoma;   Non-hodgkin's Lymphoma;   Myeloma
Interventions:   Radiation: Total Body Irradiation (TBI);   Biological: Donor Lymphocyte Infusion (DLI);   Drug: Cyclophosphamide (CY);   Drug: Tacrolimus;   Drug: Mycophenolate Mofetil (MMF);   Biological: Hematopoietic Stem Cell Transplant (HSCT)
Sponsors:   Thomas Jefferson University;   Thomas Jefferson University
Recruiting - verified April 2012

Conditions:   Accelerated Phase Chronic Myelogenous Leukemia;   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Grade III Lymphomatoid Granulomatosis;   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   Aplastic Anemia;   Burkitt Lymphoma;   Childhood Acute Lymphoblastic Leukemia in Remission;   Childhood Acute Myeloid Leukemia in Remission;   Childhood Chronic Myelogenous Leukemia;   Childhood Diffuse Large Cell Lymphoma;   Childhood Grade III Lymphomatoid Granulomatosis;   Childhood Immunoblastic Large Cell Lymphoma;   Childhood Myelodysplastic Syndromes;   Childhood Nasal Type Extranodal NK/T-cell Lymphoma;   Chronic Myelomonocytic Leukemia;   Chronic Phase Chronic Myelogenous Leukemia;   Congenital Amegakaryocytic Thrombocytopenia;   Diamond-Blackfan Anemia;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Hepatosplenic T-cell Lymphoma;   Juvenile Myelomonocytic Leukemia;   Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable;   Nodal Marginal Zone B-cell Lymphoma;   Paroxysmal Nocturnal Hemoglobinuria;   Peripheral T-cell Lymphoma;   Polycythemia Vera;   Post-transplant Lymphoproliferative Disorder;   Previously Treated Myelodysplastic Syndromes;   Primary Myelofibrosis;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Adult T-cell Leukemia/Lymphoma;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Recurrent Childhood Anaplastic Large Cell Lymphoma;   Recurrent Childhood Grade III Lymphomatoid Granulomatosis;   Recurrent Childhood Large Cell Lymphoma;   Recurrent Childhood Lymphoblastic Lymphoma;   Recurrent Childhood Small Noncleaved Cell Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Recurrent/Refractory Childhood Hodgkin Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Hairy Cell Leukemia;   Refractory Multiple Myeloma;   Secondary Acute Myeloid Leukemia;   Secondary Myelodysplastic Syndromes;   Secondary Myelofibrosis;   Severe Combined Immunodeficiency;   Severe Congenital Neutropenia;   Shwachman-Diamond Syndrome;   Splenic Marginal Zone Lymphoma;   T-cell Large Granular Lymphocyte Leukemia;   Waldenstrom Macroglobulinemia;   Wiskott-Aldrich Syndrome
Interventions:   Drug: fludarabine phosphate;   Drug: melphalan;   Radiation: total-body irradiation;   Drug: tacrolimus;   Drug: mycophenolate mofetil;   Drug: methotrexate;   Other: laboratory biomarker analysis;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation
Sponsors:   Roswell Park Cancer Institute;   Roswell Park Cancer Institute
Recruiting - verified March 2012

Conditions:   Leukemia;   Lymphoma;   Myeloma;   Myeloproliferative Diseases
Interventions:   Drug: Fludarabine;   Drug: Melphalan;   Drug: Alemtuzumab;   Procedure: Stem Cell Infusion;   Drug: Tacrolimus;   Drug: Methotrexate;   Drug: G-CSF;   Procedure: Low Dose Donor T-Cells;   Procedure: High Dose Donor T-Cells
Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center
Recruiting - verified March 2012

Condition:   Kidney Transplant
Interventions:   Drug: Tacrolimus Withdrawal +MMF +Prednisone;   Drug: MMF/Tacrolimus/Prednisone
Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified January 2012

Conditions:   Leukemia;   Lymphoma
Interventions:   Drug: Rituximab;   Drug: 111In Ibritumumab;   Procedure: Planar Scintigraphy Imaging;   Drug: 90Y IbritumumabTiuxetan;   Drug: Fludarabine;   Drug: Bendamustine;   Drug: Thymoglobulin;   Drug: Tacrolimus;   Drug: Methotrexate;   Drug: Mycophenolate;   Drug: G-CSF;   Procedure: Stem Cell Transplantation
Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center;   Spectrum Pharmaceuticals, Inc
Not yet recruiting - verified May 2012

Conditions:   Acute Myelogenous Leukemia;   Acute Lymphocytic Leukemia;   Myelodysplastic Syndrome
Interventions:   Drug: atorvastatin;   Drug: Tacrolimus;   Drug: methotrexate
Sponsors:   Ohio State University Comprehensive Cancer Center;   Ohio State University Comprehensive Cancer Center
Recruiting - verified January 2012

Conditions:   Disorder Related to Bone Marrow Transplantation;   Leukemia;   Transplantation Infection
Interventions:   Drug: Fludarabine;   Drug: Clofarabine;   Drug: Busulfan;   Drug: Thymoglobulin;   Procedure: Stem Cell Infusion;   Drug: Tacrolimus;   Drug: Methotrexate
Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center
Recruiting - verified March 2012

Conditions:   Blood And Marrow Transplantation;   Leukemia;   Lymphoma;   Transplantation Infection;   Transplantation, Bone Marrow
Interventions:   Drug: Melphalan;   Drug: Thiotepa;   Drug: Fludarabine;   Drug: Mycophenolate mofetil;   Drug: Tacrolimus;   Procedure: Cord Blood Infusion;   Drug: Rituximab
Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center
Not yet recruiting - verified April 2012

Conditions:   Renal Failure;   Tremors
Interventions:   Drug: Prograf;   Drug: LCP-Tacro
Sponsors:   Veloxis Pharmaceuticals;   Veloxis Pharmaceuticals
Recruiting - verified April 2012

Conditions:   Amputation, Traumatic;   Wounds and Injuries;   Hand Injuries
Interventions:   Procedure: Deceased donor hand transplantation;   Drug: Bone marrow cell-based therapy & single-drug immunosuppression.
Sponsors:   Johns Hopkins University;   Johns Hopkins University
Recruiting - verified October 2011

Condition:   Kidney Transplantation
Interventions:   Drug: Alemtuzumab induction; MMF + Tacrolimus maintenance;   Drug: Alemtuzumab induction; MMF + Belatacept maintenance;   Drug: Basiliximab induction; Short-term (3 months)Tacrolimus; MMF + Belatacept maintenance
Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified November 2011

Conditions:   Accelerated Phase Chronic Myelogenous Leukemia;   Adult Acute Lymphoblastic Leukemia;   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Grade III Lymphomatoid Granulomatosis;   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   Chronic Myelomonocytic Leukemia;   Chronic Phase Chronic Myelogenous Leukemia;   Contiguous Stage II Adult Burkitt Lymphoma;   Contiguous Stage II Adult Diffuse Large Cell Lymphoma;   Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma;   Stage II Adult Diffuse Small Cleaved Cell Lymphoma;   Stage II Adult Immunoblastic Large Cell Lymphoma;   Contiguous Stage II Adult Lymphoblastic Lymphoma;   Contiguous Stage II Grade 1 Follicular Lymphoma;   Contiguous Stage II Grade 2 Follicular Lymphoma;   Contiguous Stage II Grade 3 Follicular Lymphoma;   Contiguous Stage II Mantle Cell Lymphoma;   Cutaneous B-cell Non-Hodgkin Lymphoma;   de Novo Myelodysplastic Syndromes;   Hepatosplenic T-cell Lymphoma;   Intraocular Lymphoma;   Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable;   Nodal Marginal Zone B-cell Lymphoma;   Noncontiguous Stage II Adult Burkitt Lymphoma;   Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma;   Noncontiguous Stage II Adult Lymphoblastic Lymphoma;   Noncontiguous Stage II Grade 1 Follicular Lymphoma;   Noncontiguous Stage II Grade 2 Follicular Lymphoma;   Noncontiguous Stage II Grade 3 Follicular Lymphoma;   Noncontiguous Stage II Mantle Cell Lymphoma;   Peripheral T-cell Lymphoma;   Post-transplant Lymphoproliferative Disorder;   Previously Treated Myelodysplastic Syndromes;   Primary Myelofibrosis;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Adult T-cell Leukemia/Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Hairy Cell Leukemia;   Small Intestine Lymphoma;   Splenic Marginal Zone Lymphoma;   Stage I Adult Burkitt Lymphoma;   Stage I Adult Diffuse Large Cell Lymphoma;   Stage I Adult Diffuse Mixed Cell Lymphoma;   Stage I Adult Diffuse Small Cleaved Cell Lymphoma;   Stage I Adult Hodgkin Lymphoma;   Stage I Adult Immunoblastic Large Cell Lymphoma;   Stage I Adult Lymphoblastic Lymphoma;   Stage I Adult T-cell Leukemia/Lymphoma;   Stage I Chronic Lymphocytic Leukemia;   Stage I Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage I Grade 1 Follicular Lymphoma;   Stage I Grade 2 Follicular Lymphoma;   Stage I Grade 3 Follicular Lymphoma;   Stage I Mantle Cell Lymphoma;   Stage I Marginal Zone Lymphoma;   Stage I Multiple Myeloma;   Stage I Mycosis Fungoides/Sezary Syndrome;   Stage I Small Lymphocytic Lymphoma;   Stage II Adult Hodgkin Lymphoma;   Stage II Adult T-cell Leukemia/Lymphoma;   Stage II Chronic Lymphocytic Leukemia;   Stage II Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage II Multiple Myeloma;   Stage II Mycosis Fungoides/Sezary Syndrome;   Stage III Adult Burkitt Lymphoma;   Stage III Adult Diffuse Large Cell Lymphoma;   Stage III Adult Diffuse Mixed Cell Lymphoma;   Stage III Adult Diffuse Small Cleaved Cell Lymphoma;   Stage III Adult Hodgkin Lymphoma;   Stage III Adult Immunoblastic Large Cell Lymphoma;   Stage III Adult Lymphoblastic Lymphoma;   Stage III Adult T-cell Leukemia/Lymphoma;   Stage III Chronic Lymphocytic Leukemia;   Stage III Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage III Grade 1 Follicular Lymphoma;   Stage III Grade 2 Follicular Lymphoma;   Stage III Grade 3 Follicular Lymphoma;   Stage III Mantle Cell Lymphoma;   Stage III Marginal Zone Lymphoma;   Stage III Multiple Myeloma;   Stage III Mycosis Fungoides/Sezary Syndrome;   Stage III Small Lymphocytic Lymphoma;   Stage IV Adult Burkitt Lymphoma;   Stage IV Adult Diffuse Large Cell Lymphoma;   Stage IV Adult Diffuse Mixed Cell Lymphoma;   Stage IV Adult Diffuse Small Cleaved Cell Lymphoma;   Stage IV Adult Hodgkin Lymphoma;   Stage IV Adult Immunoblastic Large Cell Lymphoma;   Stage IV Adult Lymphoblastic Lymphoma;   Stage IV Adult T-cell Leukemia/Lymphoma;   Stage IV Chronic Lymphocytic Leukemia;   Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage IV Grade 1 Follicular Lymphoma;   Stage IV Grade 2 Follicular Lymphoma;   Stage IV Grade 3 Follicular Lymphoma;   Stage IV Mantle Cell Lymphoma;   Stage IV Marginal Zone Lymphoma;   Stage IV Mycosis Fungoides/Sezary Syndrome;   Stage IV Small Lymphocytic Lymphoma;   T-cell Large Granular Lymphocyte Leukemia;   Testicular Lymphoma;   Waldenstrom Macroglobulinemia
Interventions:   Drug: tacrolimus;   Biological: anti-thymocyte globulin;   Other: laboratory biomarker analysis;   Other: flow cytometry;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation
Sponsors:   Barbara Ann Karmanos Cancer Institute;   Barbara Ann Karmanos Cancer Institute
Recruiting - verified April 2012

Conditions:   Leukemia;   Chronic Myelogenous Leukemia
Interventions:   Drug: Fludarabine;   Drug: Busulfan;   Procedure: NK cell infusion:;   Drug: Interleukin-2;   Drug: Anti-Thymocyte Globulin;   Procedure: Allogeneic related Stem Cell Transplant;   Drug: Tacrolimus;   Drug: Methotrexate
Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
Recruiting - verified April 2012

Conditions:   Hematologic Malignancies;   Acute Leukemia;   Myelodysplastic Syndrome (MDS);   Specific Subtypes of Refractory Anemia (RA) or Refractory Anemia With Ringed Sideroblasts(RARS) Subtypes;   Myeloproliferative Disorder (MPD);   Hodgkin's Lymphoma;   Non-Hodgkin's Lymphoma;   Myeloma;   Aplastic Anemia
Interventions:   Drug: Fludarabine;   Drug: Thiotepa;   Radiation: Total Body Irradiation (TBI);   Biological: Donor Lymphocyte Infusion (DLI);   Drug: Cyclophosphamide (CY);   Drug: Tacrolimus;   Drug: Mycophenolate mofetil;   Device: Hematopoietic stem cell transplantation
Sponsors:   Thomas Jefferson University;   Thomas Jefferson University
Recruiting - verified January 2012

Conditions:   Diabetes;   Immunosuppression
Intervention:   Procedure: Gastric emptying test
Sponsors:   The University of Texas, Galveston;   The University of Texas, Galveston;   Novartis Pharmaceuticals
Recruiting - verified June 2011

Condition:   Kidney Transplant Rejection
Interventions:   Drug: everolimus;   Drug: cyclosporine
Sponsors:   Novartis;   Novartis Pharmaceuticals
Not yet recruiting - verified April 2012

Condition:   Hematological Malignancies
Interventions:   Radiation: Total Body Irradiation;   Drug: Cyclophosphamide;   Drug: Tacrolimus;   Drug: Mycophenolate mofetil;   Drug: Fludarabine;   Drug: Thiotepa;   Genetic: Hematopoietic stem cell transplantation
Sponsors:   Thomas Jefferson University;   Thomas Jefferson University
Recruiting - verified January 2012

Conditions:   Hodgkin's Lymphoma;   Leukemia;   Myelodysplastic Syndrome(MDS);   Multiple Myeloma;   Non Hodgkin's Lymphoma
Intervention:   Procedure: Bone Marrow Transplant
Sponsors:   Sidney Kimmel Comprehensive Cancer Center;   Sidney Kimmel Comprehensive Cancer Center
Recruiting - verified January 2012

Conditions:   Acute Lymphocytic Leukemia;   Acute Myelogenous Leukemia;   Myelodysplastic Syndrome RAEB 1
Interventions:   Drug: Lupron;   Drug: 18F FLT;   Drug: Cyclophosphamide;   Drug: Methotrexate;   Drug: Tacrolimus;   Drug: Total Body Irradiation
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified December 2011

Conditions:   Leukemia;   Lymphoma;   Myelodysplastic Syndrome
Intervention:   Drug: Bortezomib, Tacrolimus, Methotrexate
Sponsors:   Dana-Farber Cancer Institute;   Dana-Farber Cancer Institute
Recruiting - verified May 2011

Condition:   Kidney; Complications, Allograft
Intervention:   Drug: eculizumab
Sponsors:   Yale University;   Yale University;   Alexion Pharmaceuticals
Recruiting - verified July 2011

Condition:   Acute Kidney Injury
Interventions:   Drug: ATG;   Drug: Rituximab;   Drug: Methylprednisolone;   Drug: Diphenhydramine;   Drug: Acetaminophen;   Drug: Tacrolimus;   Drug: Sirolimus;   Drug: Hydrocortisone;   Drug: Prednisone
Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   National Institute of Allergy and Infectious Diseases (NIAID);   Immune Tolerance Network (ITN)
Recruiting - verified August 2011

Condition:   Diabetes Mellitus, Type 1
Interventions:   Drug: Sirolimus;   Drug: Tacrolimus;   Drug: Mycophenolate mofetil;   Drug: Mycophenolic acid
Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   National Institute of Allergy and Infectious Diseases (NIAID);   Immune Tolerance Network (ITN)
Available - verified April 2012

Condition:   Multiple Myeloma
Interventions:   Drug: Sirolimus;   Drug: Tacrolimus;   Drug: Lenalidomide
Sponsors:   Indiana University;   Indiana University School of Medicine;   Celgene Corporation
Recruiting - verified January 2012

Condition:   Sickle Cell Disease
Interventions:   Drug: Fludarabine monophosphate;   Drug: Rituximab;   Drug: Busulfan;   Drug: ATG;   Drug: Cyclophosphamide;   Drug: Mycophenolate mofetil;   Drug: Tacrolimus
Sponsors:   Nationwide Children's Hospital;   Nationwide Children's Hospital
Recruiting - verified January 2011

Condition:   Cardiac Allograft Vasculopathy
Interventions:   Biological: Rituximab induction/conventional immunosuppression (tacrolimus, MMF, and steroid taper);   Drug: Rituximab placebo/conventional immunosuppression (tacrolimus, MMF, and steroid taper)
Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   National Institute of Allergy and Infectious Diseases (NIAID);   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified October 2011

Condition:   Hematological Malignancies
Intervention:   Drug: Tacrolimus and Thymoglobulin
Sponsors:   Barbara Ann Karmanos Cancer Institute;   Barbara Ann Karmanos Cancer Institute
Recruiting - verified March 2012

Condition:   Diabetes Mellitus, Type 1
Interventions:   Biological: Allogenic islet cells (human, U. Chicago);   Procedure: Intraportal infusion of islet cells
Sponsors:   University of Chicago;   University of Chicago
Recruiting - verified April 2011

Condition:   Liver Transplant
Interventions:   Drug: Withdrawal of Tacrolimus to mycophenolate monotherapy;   Other: data and sample collection;   Other: data and sample collection
Sponsors:   University of Wisconsin, Madison;   University of Wisconsin, Madison;   Novartis Pharmaceuticals
Recruiting - verified November 2011

Condition:   Kidney Transplant Recipients
Intervention:   Drug: mycophenolic acid
Sponsors:   University of Cincinnati;   University of Cincinnati;   Novartis Pharmaceuticals
Recruiting - verified April 2011

Condition:   Hematologic Malignancies
Interventions:   Other: Fludarabine, Cytoxan, TBI, Sirolimus;   Other: Fludarabine, Cytoxan, TBI, Sirolimus + MMF;   Other: Fludarabine, Cytoxan, TBI, Tacrolimus + MMF
Sponsors:   Sidney Kimmel Comprehensive Cancer Center;   Sidney Kimmel Comprehensive Cancer Center
Recruiting - verified January 2012

Conditions:   Complete DiGeorge Anomaly;   DiGeorge Syndrome;   DiGeorge Anomaly;   Complete DiGeorge Syndrome
Interventions:   Biological: Thymus Transplantation;   Procedure: Blood Draw
Sponsors:   Duke University;   M. Louise Markert;   National Institutes of Health (NIH);   National Institute of Allergy and Infectious Diseases (NIAID);   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified February 2012

Conditions:   Diffuse, Large B-Cell, Lymphoma;   Lymphoma, Low-Grade;   T-Cell Lymphoma;   Mantle-Cell Lymphoma;   Hodgkin's Lymphoma;   Chronic Lymphocytic Leukemia;   Lymphoma, Small Lymphocytic
Interventions:   Drug: Busulfan;   Drug: Etoposide;   Drug: Cyclophosphamide;   Drug: Mesna;   Drug: Phenytoin;   Drug: Ursodiol;   Other: Infusion of autologous peripheral blood stem cells;   Drug: Neupogen;   Drug: Fludarabine;   Drug: Busulfan;   Other: Peripheral blood stem cell transplant;   Drug: Tacrolimus;   Drug: Sirolimus;   Drug: Methotrexate
Sponsors:   Massachusetts General Hospital;   Massachusetts General Hospital;   Dana-Farber Cancer Institute
Recruiting - verified April 2012

Condition:   Kidney Graft Dysfunction
Interventions:   Drug: Cyclosporins/Tacrolimus;   Drug: Sirolimus
Sponsors:   University of Minnesota - Clinical and Translational Science Institute;   University of Minnesota - Clinical and Translational Science Institute
Recruiting - verified December 2011

Conditions:   Leukemia;   Myelodysplastic Syndromes
Interventions:   Biological: anti-thymocyte globulin;   Drug: azacitidine;   Drug: busulfan;   Drug: fludarabine phosphate;   Drug: methotrexate;   Drug: tacrolimus;   Other: laboratory biomarker analysis;   Other: pharmacological study;   Procedure: allogeneic hematopoietic stem cell transplantation
Sponsors:   National Cancer Institute (NCI);   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Kidney Transplant
Interventions:   Drug: Sirolumus;   Drug: Tacrolimus
Sponsors:   The Cleveland Clinic;   The Cleveland Clinic
Recruiting - verified January 2012

Conditions:   Refractory Multiple Myeloma;   Stage I Multiple Myeloma;   Stage II Multiple Myeloma
Interventions:   Drug: bortezomib;   Drug: fludarabine phosphate;   Other: melphalan;   Radiation: intensity-modulated radiation therapy;   Radiation: total marrow irradiation;   Radiation: tomotherapy;   Drug: tacrolimus;   Drug: sirolimus
Sponsors:   City of Hope Medical Center;   City of Hope Medical Center
Recruiting - verified March 2012

Conditions:   End Stage Renal Disease;   Renal Transplant
Interventions:   Drug: Anti-Thymocyte Globulin;   Drug: TOL101;   Drug: TOL101;   Drug: Steroids;   Drug: Tacrolimus;   Drug: Mycophenolate mofetil (MMF)
Sponsors:   Tolera Therapeutics, Inc;   Tolera Therapeutics, Inc
Recruiting - verified September 2011

Condition:   Pediatric Recipients of a Liver Transplant
Intervention:  
Sponsors:   Mount Sinai School of Medicine;   Mount Sinai School of Medicine;   Children's Hospital Medical Center, Cincinnati;   Children's Hospital of Pittsburgh;   Children's Memorial Hospital;   University of California, Los Angeles;   The EMMES Corporation
Recruiting - verified February 2012

Condition:   Liver Transplantation
Interventions:   Drug: MMF(1000mg bid) + tacrolimus + standard of care medications;   Drug: sotrastaurin (200mg bid) + tacrolimus + standard of care medications;   Drug: sotrastaurin (200mg bid) + tacrolimus + standard of care medications;   Drug: sotrastaurin (300 mg bid) + tacrolimus + standard of care medications
Sponsors:   Novartis;   Novartis Pharmaceuticals
Recruiting - verified May 2012

Conditions:   Chronic Myeloproliferative Disorders;   Graft Versus Host Disease;   Leukemia;   Lymphoma;   Lymphoproliferative Disorder;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Neoplasms
Interventions:   Biological: anti-thymocyte globulin;   Biological: rituximab;   Drug: sirolimus;   Drug: tacrolimus;   Other: laboratory biomarker analysis;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: management of therapy complications;   Procedure: peripheral blood stem cell transplantation
Sponsors:   Barbara Ann Karmanos Cancer Institute;   Barbara Ann Karmanos Cancer Institute;   National Cancer Institute (NCI)
Recruiting - verified March 2012

Condition:   Liver Transplant Recipient
Interventions:   Drug: Tacrolimus;   Drug: Tacrolimus + everolimus;   Drug: Everolimus
Sponsors:   Novartis;   Novartis Pharmaceuticals
Recruiting - verified April 2012

Condition:   Chronic GVHD
Interventions:   Drug: Sirolimus + calcineurin inhibitor + prednisone;   Drug: Sirolimus + prednisone
Sponsors:   National Heart, Lung, and Blood Institute (NHLBI);   National Heart, Lung, and Blood Institute (NHLBI);   National Cancer Institute (NCI);   Blood and Marrow Transplant Clinical Trials Network
Recruiting - verified April 2012

Condition:   CNI Side Effects
Interventions:   Drug: Cyclosporine & Cellcept;   Drug: Prograf & Cellcept;   Drug: Cyclosporine, Cellcept, & Prednisone;   Drug: Prograf, Cellcept, & Prednisone;   Drug: Low Dose CNI (Cyclosporine or FK) and Cellcept;   Drug: Rapamune and Cellcept;   Drug: Low dose CNI (CSA or FK), Rapamune, & Prednisone;   Drug: Rapamune, Cellcept, & Prednisone
Sponsors:   University of Minnesota - Clinical and Translational Science Institute;   University of Minnesota - Clinical and Translational Science Institute;   Roche Pharma AG;   Wyeth is now a wholly owned subsidiary of Pfizer;   Genzyme
Recruiting - verified April 2012

Condition:   Kidney Transplantation
Interventions:   Drug: Mycophenolic Acid;   Drug: Standard of Care: CNI and MPA
Sponsors:   University of Wisconsin, Madison;   University of Wisconsin, Madison
Recruiting - verified November 2011

Condition:   Systemic Scleroderma
Interventions:   Drug: fludarabine phosphate;   Radiation: total-body irradiation;   Drug: tacrolimus;   Drug: mycophenolate mofetil;   Biological: rituximab;   Drug: cyclophosphamide;   Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation
Sponsors:   Fred Hutchinson Cancer Research Center;   Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium;   National Cancer Institute (NCI)
Not yet recruiting - verified May 2012

Conditions:   Leukemia, Myeloid, Accelerated Phase;   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia in Remission;   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Blast Phase;   Contiguous Stage II Adult Burkitt's Lymphoma;   Contiguous Stage II Adult Diffuse Large Cell Lymphoma;   Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma;   Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma;   Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma;   Contiguous Stage II Adult Lymphoblastic Lymphoma;   Contiguous Stage II Grade 1 Follicular Lymphoma;   Contiguous Stage II Grade 2 Follicular Lymphoma;   Contiguous Stage II Grade 3 Follicular Lymphoma;   Contiguous Stage II Mantle Cell Lymphoma;   Contiguous Stage II Marginal Zone Lymphoma;   Contiguous Stage II Small Lymphocytic Lymphoma;   De Novo Myelodysplastic Syndromes;   Mucosa-Associated Lymphoid Tissue Lymphoma;   Graft Versus Host Disease;   Monocytoid B-cell Lymphoma;   Noncontiguous Stage II Adult Burkitt's Lymphoma;   Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma;   Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma;   Noncontiguous Stage II Adult Lymphoblastic Lymphoma;   Noncontiguous Stage II Grade 1 Follicular Lymphoma;   Noncontiguous Stage II Grade 2 Follicular Lymphoma;   Noncontiguous Stage II Grade 3 Follicular Lymphoma;   Noncontiguous Stage II Mantle Cell Lymphoma;   Noncontiguous Stage II Marginal Zone Lymphoma;   Noncontiguous Stage II Small Lymphocytic Lymphoma;   Previously Treated Myelodysplastic Syndromes;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Adult Burkitt's Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Adult T-cell Lymphoma/Leukaemia Recurrent;   Cutaneous T-cell Lymphoma Recurrent;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Mantle Cell Lymphoma Recurrent;   Recurrent Marginal Zone Lymphoma;   Mycosis Fungoides/Sezary Syndrome Recurrent;   B-cell Small Lymphocytic Lymphoma Recurrent;   Chronic Lymphocytic Leukaemia Refractory;   Chronic Myelogenous Leukemia in Relapse;   Secondary Myelodysplastic Syndromes;   Splenic Marginal Zone B-Cell Lymphoma;   Stage I Adult Burkitt's Lymphoma;   Stage I Adult Diffuse Large Cell Lymphoma;   Stage I Adult Diffuse Mixed Cell Lymphoma;   Stage I Adult Diffuse Small Cleaved Cell Lymphoma;   Stage I Adult Immunoblastic Large Cell Lymphoma;   Stage I Adult Lymphoblastic Lymphoma;   Adult T-cell Lymphoma/Leukaemia Stage I;   Chronic Lymphocytic Leukaemia Stage 1;   Cutaneous T-cell Lymphoma Stage I;   Stage I Grade 1 Follicular Lymphoma;   Stage I Grade 2 Follicular Lymphoma;   Stage I Grade 3 Follicular Lymphoma;   Mantle Cell Lymphoma Stage I;   Stage I Marginal Zone Lymphoma;   Mycosis Fungoides/Sezary Syndrome Stage I;   B-cell Small Lymphocytic Lymphoma Stage I;   Adult T-cell Lymphoma/Leukaemia Stage II;   Chronic Lymphocytic Leukaemia Stage 2;   Cutaneous T-cell Lymphoma Stage II;   Mycosis Fungoides/Sezary Syndrome Stage II;   Stage III Adult Burkitt's Lymphoma;   Stage III Adult Diffuse Large Cell Lymphoma;   Stage III Adult Diffuse Mixed Cell Lymphoma;   Stage III Adult Diffuse Small Cleaved Cell Lymphoma;   Stage III Adult Immunoblastic Large Cell Lymphoma;   Stage III Adult Lymphoblastic Lymphoma;   Adult T-cell Lymphoma/Leukaemia Stage III;   Chronic Lymphocytic Leukaemia Stage 3;   Cutaneous T-cell Lymphoma Stage III;   Stage III Grade 1 Follicular Lymphoma;   Stage III Grade 2 Follicular Lymphoma;   Stage III Grade 3 Follicular Lymphoma;   Mantle Cell Lymphoma Stage III;   Stage III Marginal Zone Lymphoma;   Mycosis Fungoides/Sezary Syndrome Stage III;   B-cell Small Lymphocytic Lymphoma Stage III;   Stage IV Adult Burkitt's Lymphoma;   Stage IV Adult Diffuse Large Cell Lymphoma;   Stage IV Adult Diffuse Mixed Cell Lymphoma;   Stage IV Adult Diffuse Small Cleaved Cell Lymphoma;   Stage IV Adult Immunoblastic Large Cell Lymphoma;   Stage IV Adult Lymphoblastic Lymphoma;   Adult T-cell Lymphoma/Leukaemia Stage IV;   Chronic Lymphocytic Leukaemia Stage 4;   Cutaneous T-cell Lymphoma Stage IV;   Stage IV Grade 1 Follicular Lymphoma;   Stage IV Grade 2 Follicular Lymphoma;   Stage IV Grade 3 Follicular Lymphoma;   Mantle Cell Lymphoma Stage IV;   Stage IV Marginal Zone Lymphoma;   Mycosis Fungoides/Sezary Syndrome Stage IV;   B-cell Small Lymphocytic Lymphoma Stage IV;   Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Adult Acute Myeloid Leukemia;   Waldenstrom Macroglobulinemia
Interventions:   Drug: rituximab;   Drug: mycophenolate mofetil;   Drug: tacrolimus;   Drug: anti-thymocyte globulin;   Procedure: allogeneic hematopoietic stem cell transplantation;   Other: laboratory biomarker analysis;   Biological: graft versus host disease prophylaxis/therapy;   Drug: cyclophosphamide;   Drug: fludarabine phosphate;   Drug: busulfan;   Radiation: total-body irradiation;   Biological: graft-versus-tumor induction therapy;   Biological: immunosuppressive therapy
Sponsors:   University of Nebraska;   University of Nebraska;   National Cancer Institute (NCI)
Recruiting - verified March 2011

Conditions:   Acute Undifferentiated Leukemia;   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Megakaryoblastic Leukemia (M7);   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Erythroleukemia (M6a);   Adult Pure Erythroid Leukemia (M6b);   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Refractory Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
Interventions:   Drug: fludarabine phosphate;   Drug: cyclophosphamide;   Drug: tacrolimus;   Drug: mycophenolate mofetil;   Procedure: peripheral blood stem cell transplantation;   Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation;   Procedure: laboratory biomarker analysis;   Procedure: flow cytometry;   Radiation: total-body irradiation;   Genetic: fluorescence in situ hybridization;   Genetic: western blotting;   Procedure: polymerase chain reaction;   Biological: filgrastim
Sponsors:   Fred Hutchinson Cancer Research Center;   Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium;   National Cancer Institute (NCI)
Recruiting - verified March 2012

Conditions:   Leukemia;   Lymphoma
Interventions:   Biological: anti-thymocyte globulin;   Biological: rituximab;   Drug: busulfan;   Drug: cyclophosphamide;   Drug: fludarabine phosphate;   Drug: methotrexate;   Drug: sirolimus;   Drug: tacrolimus;   Other: laboratory biomarker analysis;   Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation
Sponsors:   National Cancer Institute (NCI);   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Conditions:   Blood Stem Cell Transplant Failure;   Leukemia;   Hematologic Malignancies
Interventions:   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: Melphalan;   Drug: Mesna;   Drug: Rituximab;   Procedure: Stem Cell Transplantation;   Drug: Thiotepa;   Drug: Tacrolimus;   Drug: Mycofenolate mofetil
Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center
Recruiting - verified May 2012

Conditions:   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   B-cell Chronic Lymphocytic Leukemia;   Burkitt Lymphoma;   Childhood Diffuse Large Cell Lymphoma;   Childhood Immunoblastic Large Cell Lymphoma;   Childhood Nasal Type Extranodal NK/T-cell Lymphoma;   Cutaneous B-cell Non-Hodgkin Lymphoma;   Peripheral T-cell Lymphoma;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Childhood Anaplastic Large Cell Lymphoma;   Recurrent Childhood Grade III Lymphomatoid Granulomatosis;   Recurrent Childhood Large Cell Lymphoma;   Recurrent Childhood Lymphoblastic Lymphoma;   Recurrent Childhood Small Noncleaved Cell Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Recurrent/Refractory Childhood Hodgkin Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Multiple Myeloma;   Splenic Marginal Zone Lymphoma;   Waldenstrom Macroglobulinemia
Interventions:   Drug: carmustine;   Drug: etoposide;   Drug: cytarabine;   Drug: fludarabine phosphate;   Drug: cyclophosphamide;   Drug: tacrolimus;   Drug: mycophenolate mofetil;   Radiation: total-body irradiation;   Drug: melphalan;   Procedure: autologous-allogeneic tandem hematopoietic stem cell transplantation;   Procedure: autologous hematopoietic stem cell transplantation;   Procedure: allogeneic bone marrow transplantation;   Genetic: fluorescence in situ hybridization;   Other: flow cytometry;   Genetic: RNA analysis;   Other: laboratory biomarker analysis;   Genetic: cytogenetic analysis;   Genetic: polymerase chain reaction;   Procedure: allogeneic peripheral blood mononuclear stem cell transplantation
Sponsors:   Fred Hutchinson Cancer Research Center;   Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium;   National Cancer Institute (NCI)
Recruiting - verified February 2012

Conditions:   Glomerular Filtration Rate;   Chronic Allograft Nephropathy
Intervention:   Drug: sirolimus
Sponsors:   Temple University;   Temple University;   Wyeth is now a wholly owned subsidiary of Pfizer
Recruiting - verified October 2009

Condition:   Kidney Transplantation
Interventions:   Drug: rapamune, mycophenolate mofetil and steroid;   Drug: tacrolimus, sirolimus and steroid
Sponsors:   Medical University of South Carolina;   Medical University of South Carolina;   Wyeth is now a wholly owned subsidiary of Pfizer
Recruiting - verified April 2012

Condition:   Kidney Transplantation
Interventions:   Drug: Prograf;   Drug: Neoral
Sponsors:   Loma Linda University;   Loma Linda University
Recruiting - verified June 2011

Conditions:   Leukemia;   Non-Hodgkins Lymphoma;   Hodgkins Lymphoma;   MDS;   Multiple Myeloma
Interventions:   Drug: EPOCH-F/R;   Drug: FLAG;   Drug: Transplant Preparative Regimen (Flu/Cy/Mes);   Drug: GVHD Prophylaxis (tacrolimus and sirolimus);   Procedure: Double Cord Blood Transplantation
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified February 2012

Condition:   Peripheral Nerve Injury
Intervention:   Drug: Tacrolimus
Sponsors:   Washington University School of Medicine;   Washington University School of Medicine
Not yet recruiting - verified January 2010

Conditions:   Lymphoma;   B-cell Lymphoma;   Non Hodgkin Lymphoma;   Chronic Lymphocytic Leukemia
Intervention:   Drug: Bone marrow transplantation
Sponsors:   Sidney Kimmel Comprehensive Cancer Center;   Sidney Kimmel Comprehensive Cancer Center
Recruiting - verified January 2012

Condition:   Kidney Transplant
Interventions:   Drug: Tacrolimus;   Drug: Sirolimus (Rapamune, Rapamycin);   Drug: Mycophenolate Mofetil + Prednisone
Sponsors:   Mayo Clinic;   Mayo Clinic;   Wyeth is now a wholly owned subsidiary of Pfizer
Recruiting - verified December 2011

Conditions:   Kidney Transplant;   Delayed Graft Function;   Slow Graft Function-defined at Creatinine >= 3.0 by Post-op Day 5 Without Requiring Dialysis
Interventions:   Drug: Tacrolimus (FK506, Prograf);   Drug: Sirolimus (Rapamune, Rapamycin)
Sponsors:   University of Maryland;   University of Maryland;   Wyeth is now a wholly owned subsidiary of Pfizer
Recruiting - verified December 2009

Conditions:   Non-hodgkin Lymphoma;   Hodgkin Lymphoma
Interventions:   Drug: Sirolimus;   Drug: Methotrexate;   Drug: Tacrolimus;   Drug: Cyclosporine;   Drug: Mycophenolate mofetil
Sponsors:   Dana-Farber Cancer Institute;   Dana-Farber Cancer Institute;   Brigham and Women's Hospital;   Massachusetts General Hospital;   National Cancer Institute (NCI)
Recruiting - verified January 2012

Conditions:   Reduction in Sequelae Related to Calcineurin Inhibitors;   Chimeric Antibody Sensitization;   Allograft Rejection
Interventions:   Drug: basiliximab;   Drug: basiliximab
Sponsors:   Drexel University;   Drexel University College of Medicine;   Novartis
Recruiting - verified May 2011

Conditions:   MonoMAC;   Myelodysplastic Syndrome;   Immunodeficiency
Interventions:   Procedure: Reduced-Intensity Hematopoietic Stem Cell;   Drug: Fludarabine;   Procedure: Total Body Irradiation (TBI);   Drug: Filgrastim;   Drug: Sirolimus;   Drug: Tacrolimus;   Drug: Ursodiol
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified January 2012

Condition:   Nonmalignant Neoplasm
Interventions:   Procedure: umbilical cord blood transplantation;   Procedure: peripheral blood stem cell transplantation;   Procedure: allogeneic bone marrow transplantation;   Drug: fludarabine phosphate;   Drug: treosulfan;   Radiation: total-body irradiation;   Drug: tacrolimus;   Drug: methotrexate;   Drug: cyclosporine;   Drug: mycophenolate mofetil;   Genetic: DNA analysis;   Other: laboratory biomarker analysis;   Genetic: cytogenetic analysis;   Biological: anti-thymocyte globulin
Sponsors:   Fred Hutchinson Cancer Research Center;   Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium;   National Cancer Institute (NCI);   National Heart, Lung, and Blood Institute (NHLBI);   medac GmbH
Recruiting - verified April 2012

Conditions:   Graft Versus Host Disease;   Leukemia;   Myelodysplastic Syndromes
Interventions:   Drug: Fludarabine Phosphate;   Drug: Tacrolimus;   Drug: Thiotepa;   Radiation: Total-Body Irradiation (TBI);   Other: Magnetic Affinity Cell Sorting;   Procedure: Peripheral Blood Stem Cell Transplantation;   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Biological: T Cell-Depleted Hematopoietic Stem Cell Transplantation
Sponsors:   Yale University;   Yale University;   National Cancer Institute (NCI);   Fred Hutchinson Cancer Research Center
Recruiting - verified January 2011

Condition:   Lymphoma, Non-Hodgkin
Intervention:   Biological: Hematopoietic Stem Cell Transplant
Sponsors:   National Heart, Lung, and Blood Institute (NHLBI);   National Heart, Lung, and Blood Institute (NHLBI);   Blood and Marrow Transplant Clinical Trials Network;   National Cancer Institute (NCI)
Recruiting - verified January 2012

Condition:   Lymphoma, Non-Hodgkin
Interventions:   Procedure: Autologous Transplant;   Procedure: Allogeneic Transplant
Sponsors:   Washington University School of Medicine;   Washington University School of Medicine
Recruiting - verified September 2011

Condition:   Neuroblastoma
Interventions:   Other: anti-thymocyte globulin;   Drug: busulfan;   Drug: cyclosporine;   Drug: fludarabine phosphate;   Drug: mycophenolate mofetil;   Drug: tacrolimus;   Procedure: allogeneic hematopoietic stem cell transplantation
Sponsors:   Nationwide Children's Hospital;   Nationwide Children's Hospital
Recruiting - verified January 2011

Condition:   Renal Transplant Rejection
Intervention:   Drug: Sirolimus
Sponsors:   Northwestern University;   Northwestern University;   Wyeth is now a wholly owned subsidiary of Pfizer
Recruiting - verified April 2011

Conditions:   Accelerated Phase Chronic Myelogenous Leukemia;   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Blastic Phase Chronic Myelogenous Leukemia;   Childhood Acute Myeloid Leukemia in Remission;   Childhood Chronic Myelogenous Leukemia;   Childhood Myelodysplastic Syndromes;   Chronic Myelomonocytic Leukemia;   de Novo Myelodysplastic Syndromes;   Previously Treated Myelodysplastic Syndromes;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Secondary Myelodysplastic Syndromes
Interventions:   Drug: treosulfan;   Drug: fludarabine phosphate;   Radiation: total-body irradiation;   Procedure: peripheral blood stem cell transplantation;   Drug: tacrolimus;   Procedure: allogeneic bone marrow transplantation;   Procedure: allogeneic hematopoietic stem cell transplantation;   Drug: methotrexate
Sponsors:   Fred Hutchinson Cancer Research Center;   Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium;   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified March 2012

Conditions:   Side Effects of Calcineurin Inhibitors;   Renal Toxicity;   Hepatic Fibrosis on Biopsy;   Neurotoxicity;   Post Transplant Diabetes
Intervention:   Procedure: Liver biopsy
Sponsors:   Thomas Jefferson University;   Thomas Jefferson University;   Wyeth is now a wholly owned subsidiary of Pfizer
Recruiting - verified February 2009

Conditions:   Hematologic Malignancies;   Graft vs Host Disease
Interventions:   Procedure: reduced intensity, matched related donor stem cell transplant;   Drug: tacrolimus (standard GVHD prophylaxis);   Drug: mycophenolate (standard GVHD prophylaxis);   Drug: vorinostat
Sponsors:   University of Michigan Cancer Center;   Pavan Reddy, MD
Recruiting - verified February 2012

Conditions:   Stem Cell Transplantation;   Leukemia
Interventions:   Drug: Fludarabine;   Drug: Busulfan;   Drug: Thymoglobulin;   Drug: Azacitidine;   Procedure: Stem Cell Transplant
Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
Recruiting - verified December 2011

Conditions:   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative;   Burkitt Lymphoma;   Childhood Acute Lymphoblastic Leukemia in Remission;   Childhood Acute Myeloid Leukemia in Remission;   Childhood Diffuse Large Cell Lymphoma;   Childhood Immunoblastic Large Cell Lymphoma;   Childhood Myelodysplastic Syndromes;   Childhood Nasal Type Extranodal NK/T-cell Lymphoma;   Chronic Myelomonocytic Leukemia;   Contiguous Stage II Adult Burkitt Lymphoma;   Contiguous Stage II Adult Diffuse Large Cell Lymphoma;   Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma;   Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma;   Contiguous Stage II Adult Lymphoblastic Lymphoma;   Contiguous Stage II Grade 3 Follicular Lymphoma;   Cutaneous B-cell Non-Hodgkin Lymphoma;   de Novo Myelodysplastic Syndromes;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Hepatosplenic T-cell Lymphoma;   Juvenile Myelomonocytic Leukemia;   Myelodysplastic Syndrome With Isolated Del(5q);   Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable;   Nodal Marginal Zone B-cell Lymphoma;   Noncontiguous Stage II Adult Burkitt Lymphoma;   Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma;   Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma;   Noncontiguous Stage II Adult Lymphoblastic Lymphoma;   Noncontiguous Stage II Grade 3 Follicular Lymphoma;   Peripheral T-cell Lymphoma;   Plasma Cell Neoplasm;   Previously Treated Myelodysplastic Syndromes;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Adult T-cell Leukemia/Lymphoma;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Recurrent Childhood Anaplastic Large Cell Lymphoma;   Recurrent Childhood Grade III Lymphomatoid Granulomatosis;   Recurrent Childhood Large Cell Lymphoma;   Recurrent Childhood Lymphoblastic Lymphoma;   Recurrent Childhood Small Noncleaved Cell Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Recurrent/Refractory Childhood Hodgkin Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Multiple Myeloma;   Relapsing Chronic Myelogenous Leukemia;   Secondary Myelodysplastic Syndromes;   Small Intestine Lymphoma;   Splenic Marginal Zone Lymphoma;   Stage I Adult Burkitt Lymphoma;   Stage I Adult Diffuse Large Cell Lymphoma;   Stage I Adult Diffuse Mixed Cell Lymphoma;   Stage I Adult Immunoblastic Large Cell Lymphoma;   Stage I Adult Lymphoblastic Lymphoma;   Stage I Childhood Large Cell Lymphoma;   Stage I Childhood Lymphoblastic Lymphoma;   Stage I Childhood Small Noncleaved Cell Lymphoma;   Stage I Grade 3 Follicular Lymphoma;   Stage II Childhood Large Cell Lymphoma;   Stage II Childhood Lymphoblastic Lymphoma;   Stage II Childhood Small Noncleaved Cell Lymphoma;   Stage III Adult Burkitt Lymphoma;   Stage III Adult Diffuse Large Cell Lymphoma;   Stage III Adult Diffuse Mixed Cell Lymphoma;   Stage III Adult Immunoblastic Large Cell Lymphoma;   Stage III Adult Lymphoblastic Lymphoma;   Stage III Childhood Large Cell Lymphoma;   Stage III Childhood Lymphoblastic Lymphoma;   Stage III Childhood Small Noncleaved Cell Lymphoma;   Stage III Grade 3 Follicular Lymphoma;   Stage IV Adult Burkitt Lymphoma;   Stage IV Adult Diffuse Large Cell Lymphoma;   Stage IV Adult Diffuse Mixed Cell Lymphoma;   Stage IV Adult Immunoblastic Large Cell Lymphoma;   Stage IV Adult Lymphoblastic Lymphoma;   Stage IV Childhood Large Cell Lymphoma;   Stage IV Childhood Lymphoblastic Lymphoma;   Stage IV Childhood Small Noncleaved Cell Lymphoma;   Stage IV Grade 3 Follicular Lymphoma;   Testicular Lymphoma;   Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Adult Acute Myeloid Leukemia;   Untreated Childhood Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies;   Waldenstrom Macroglobulinemia
Interventions:   Drug: fludarabine phosphate;   Drug: cyclophosphamide;   Drug: mycophenolate mofetil;   Drug: tacrolimus;   Radiation: total-body irradiation;   Procedure: allogeneic bone marrow transplantation;   Biological: natural killer cell therapy;   Genetic: fluorescence in situ hybridization;   Genetic: cytogenetic analysis
Sponsors:   Fred Hutchinson Cancer Research Center;   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
Recruiting - verified January 2012

Conditions:   MDS;   Leukemias;   Lymphomas
Intervention:   Drug: Drug: busulfan, Cyclophosphamide, Total Body Irradiation
Sponsors:   Sidney Kimmel Comprehensive Cancer Center;   Sidney Kimmel Comprehensive Cancer Center;   Otsuka Pharmaceutical Co., Ltd.;   National Center for Research Resources (NCRR)
Recruiting - verified January 2012

Condition:   Hematologic Neoplasms
Interventions:   Procedure: full intensity, double umbilical cord, stem cell transplant;   Drug: Flu/Bu4 conditioning regimen;   Radiation: Total Lymphoid Irradiation (TLI);   Drug: Graft versus Host Disease prevention (GVHD prophylaxis)
Sponsors:   University of Michigan Cancer Center;   University of Michigan Cancer Center
Recruiting - verified March 2011

Condition:   Sickle Cell Disease
Intervention:   Biological: Hematopoietic Stem Cell Transplantation
Sponsors:   National Heart, Lung, and Blood Institute (NHLBI);   National Heart, Lung, and Blood Institute (NHLBI);   Blood and Marrow Transplant Clinical Trials Network;   National Cancer Institute (NCI);   National Marrow Donor Program;   Sickle Cell Disease Clinical Research Network
Recruiting - verified March 2012

Conditions:   Kidney Transplant;   Immunosuppression
Intervention:   Drug: Tacrolimus
Sponsors:   Weill Medical College of Cornell University;   Weill Medical College of Cornell University;   Genzyme
Recruiting - verified August 2011

Conditions:   Immunosuppression;   Kidney Transplantation
Intervention:  
Sponsors:   Northwestern University;   Northwestern University
Recruiting - verified February 2009

Condition:   Oral Chronic Graft-versus-host Disease
Interventions:   Drug: Tacrolimus;   Drug: Dexamethasone
Sponsors:   Dana-Farber Cancer Institute;   Brigham and Women's Hospital;   Dana-Farber Cancer Institute;   Children's Hospital Boston;   Beth Israel Deaconess Medical Center;   Massachusetts General Hospital
Recruiting - verified February 2011

Condition:   Type 1 Diabetes Mellitus
Intervention:   Drug: Islets of Langerhans transplantation
Sponsors:   University of Illinois;   University of Illinois
Recruiting - verified August 2011

Conditions:   Graft vs Host Disease;   Peripheral Blood Stem Cell Transplantation;   Transplantation, Homologous
Interventions:   Drug: Tacrolimus;   Drug: Sirolimus;   Drug: Bortezomib
Sponsors:   Indiana University;   Indiana University School of Medicine;   Millennium Pharmaceuticals, Inc.
Recruiting - verified January 2012

Conditions:   Leukemia;   Lymphoma;   Bone Marrow Failure;   Immunodeficiencies;   Histiocytosis
Interventions:   Drug: Full Intensity with TBI;   Drug: Full Intensity;   Drug: Reduced Intensity;   Drug: Reduced Intensity (Fanconi)
Sponsors:   New York Medical College;   New York Medical College
Recruiting - verified April 2012

Conditions:   Non-Hodgkin's Lymphoma;   Hodgkins Disease
Interventions:   Drug: Fludarabine and Busulfan;   Drug: Fludarabine, Busulfan and ATG
Sponsors:   Columbia University;   Columbia University;   Duke University
Recruiting - verified January 2012

Condition:   Atopic Dermatitis
Intervention:   Drug: tacrolimus ointment
Sponsors:   Wake Forest University;   Wake Forest University
Recruiting - verified January 2009

Condition:   Graft Versus Host Disease
Interventions:   Procedure: stem cell transplant;   Drug: tacrolimus (standard GVHD prophylaxis);   Drug: mycophenolate (standard GVHD prophylaxis);   Drug: etanercept;   Drug: methoxsalen
Sponsors:   University of Michigan Cancer Center;   University of Michigan Cancer Center;   Therakos;   Amgen
Recruiting - verified November 2011

Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Neoplasms;   Precancerous Condition
Interventions:   Biological: alemtuzumab;   Drug: busulfan;   Drug: fludarabine phosphate;   Drug: tacrolimus;   Procedure: allogeneic hematopoietic stem cell transplantation
Sponsors:   National Cancer Institute (NCI);   Baylor College of Medicine
Recruiting - verified June 2009

Conditions:   Systemic Scleroderma;   Severe Systemic Sclerosis
Interventions:   Drug: fludarabine phosphate;   Drug: Mycophenolic Acid;   Drug: tacrolimus;   Radiation: total-body irradiation;   Procedure: bone marrow transplantation;   Procedure: reduced intensity allogeneic hematopoietic stem cell transplantation;   Procedure: quality-of-life assessment;   Other: laboratory biomarker analysis;   Other: flow cytometry;   Procedure: biopsy;   Drug: cyclophosphamide
Sponsors:   Fred Hutchinson Cancer Research Center;   Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium;   National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified April 2012

Condition:   Graft Versus Host Disease
Interventions:   Drug: Rapamycin;   Drug: Tacrolimus
Sponsors:   Yale University;   Yale University;   Wyeth is now a wholly owned subsidiary of Pfizer
Recruiting - verified June 2009

Condition:   Stem Cell Transplantation
Interventions:   Drug: tacrolimus;   Drug: Sirolimus;   Drug: Methotrexate
Sponsors:   Yale University;   Yale University
Recruiting - verified June 2009

Condition:   Nonmalignant Neoplasm
Interventions:   Biological: alemtuzumab;   Drug: cyclophosphamide;   Drug: methotrexate;   Drug: tacrolimus;   Procedure: allogeneic bone marrow transplantation;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation;   Radiation: total-body irradiation
Sponsors:   National Cancer Institute (NCI);   Baylor College of Medicine
Recruiting - verified June 2009

Conditions:   Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome;   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Chronic Myelomonocytic Leukemia;   de Novo Myelodysplastic Syndromes;   Previously Treated Myelodysplastic Syndromes;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Refractory Anemia With Excess Blasts;   Refractory Anemia With Ringed Sideroblasts;   Refractory Cytopenia With Multilineage Dysplasia;   Secondary Acute Myeloid Leukemia;   Secondary Myelodysplastic Syndromes
Interventions:   Drug: fludarabine phosphate;   Drug: cyclophosphamide;   Radiation: total-body irradiation;   Radiation: iodine I 131 monoclonal antibody BC8;   Procedure: allogeneic bone marrow transplantation;   Drug: tacrolimus;   Drug: mycophenolate mofetil;   Other: laboratory biomarker analysis;   Other: flow cytometry;   Genetic: cytogenetic analysis
Sponsors:   Fred Hutchinson Cancer Research Center;   Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium;   National Cancer Institute (NCI)
Recruiting - verified April 2012

Condition:   Aplastic Anemia
Interventions:   Drug: Cytoxan;   Drug: Campath;   Radiation: Total Body Irradiation (TBI);   Drug: FK-506;   Drug: Methotrexate;   Procedure: Stem cell infusion
Sponsors:   Baylor College of Medicine;   Baylor College of Medicine;   The Methodist Hospital System;   Texas Children's Hospital;   Center for Cell and Gene Therapy, Baylor College of Medicine
Recruiting - verified May 2012

Conditions:   Leukemia;   Hodgkin Lymphoma;   Non Hodgkin Lymphoma;   Myeloproliferative Disorders
Interventions:   Drug: Ara C;   Drug: Cyclophosphamide;   Drug: MESNA;   Procedure: TBI;   Biological: Campath-1h;   Procedure: Stem Cell Infusion;   Drug: Tacrolimus;   Drug: Methotrexate
Sponsors:   Baylor College of Medicine;   Baylor College of Medicine
Recruiting - verified April 2012

Conditions:   Leukemia;   Cancer;   Lymphoma
Interventions:   Drug: Ara-C;   Drug: Cytoxan;   Drug: Mesna;   Radiation: TBI Fraction;   Procedure: Stem Cell Infusion;   Drug: Methotrexate;   Drug: Tacrolimus
Sponsors:   Baylor College of Medicine;   Baylor College of Medicine;   Texas Children's Hospital
Recruiting - verified April 2012

Conditions:   Graft Versus Host Disease;   Leukemia;   Lymphoma
Interventions:   Biological: rituximab;   Drug: fludarabine phosphate;   Drug: melphalan;   Drug: sirolimus;   Drug: tacrolimus;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation;   Radiation: indium In 111 ibritumomab tiuxetan;   Radiation: yttrium Y 90 ibritumomab tiuxetan
Sponsors:   City of Hope Medical Center;   City of Hope Medical Center;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Kidney Transplant
Intervention:   Drug: Myfortic
Sponsors:   University of Utah;   University of Utah
Recruiting - verified March 2011

Condition:   Anemia, Aplastic
Intervention:   Drug: Cyclophosphamide,Campath IH and TBI
Sponsors:   Mayo Clinic;   Mayo Clinic
Recruiting - verified December 2010

Condition:   Atopic Dermatitis
Intervention:   Drug: Pimecrolimus
Sponsors:   Valeant Pharmaceuticals International, Inc.;   Valeant Pharmaceuticals International, Inc.;   Clinical Research Computing Unit (University of Pennsylvania)
Recruiting - verified May 2012

Condition:   Leukemia
Interventions:   Biological: anti-thymocyte globulin;   Drug: busulfan;   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: methotrexate;   Drug: methylprednisolone;   Drug: tacrolimus;   Other: laboratory biomarker analysis;   Other: pharmacological study;   Procedure: allogeneic bone marrow transplantation
Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified April 2011

Condition:   Renal Transplant
Intervention:   Drug: Sirolimus
Sponsors:   Pediatric Nephrology of Alabama;   Pediatric Nephrology of Alabama;   Pfizer;   The EMMES Corporation
Recruiting - verified May 2011

Condition:   Type 1 Diabetes
Interventions:   Drug: Rapamycin;   Drug: Tacrolimus and mycophenolate mofetil;   Drug: SRL and TAC;   Drug: Mycophenolate Mofetil
Sponsors:   University of Miami;   University of Miami;   Astellas Pharma Inc
Recruiting - verified September 2007

Conditions:   Myelodysplastic Syndrome;   Hodgkin's Lymphoma;   Non-Hodgkin's Disease;   Acute Leukemia;   Multiple Myeloma
Interventions:   Drug: Cyclophosphamide;   Biological: rituximab;   Drug: Methotrexate;   Drug: Sirolimus;   Drug: Cyclosporine;   Drug: Doxorubicin hydrochloride;   Drug: Etoposide;   Drug: Fludarabine phosphate;   Drug: Prednisone;   Drug: Vincristine sulfate;   Drug: Cytarabine;   Drug: Tacrolimus;   Biological: Alemtuzumab
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified June 2011

Conditions:   Chronic Myeloproliferative Disorders;   Graft Versus Host Disease;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Neoplasms
Interventions:   Drug: busulfan;   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: etoposide;   Drug: methotrexate;   Drug: rasburicase;   Drug: sirolimus;   Drug: tacrolimus;   Other: diagnostic laboratory biomarker analysis;   Other: flow cytometry;   Other: immunologic technique;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation;   Radiation: total-body irradiation
Sponsors:   National Cancer Institute (NCI);   Massachusetts General Hospital
Recruiting - verified April 2008

Condition:   Atopic Dermatitis
Intervention:  
Sponsors:   Astellas Pharma Inc;   Astellas Pharma Inc
Recruiting - verified March 2012

Condition:   Aplastic Anemia
Interventions:   Drug: Antithymocyte Globulin;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Radiation: Total Body Irradiation (TBI);   Procedure: Bone Marrow Transplant
Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center;   National Heart, Lung, and Blood Institute (NHLBI);   National Cancer Institute (NCI)
Recruiting - verified April 2012

Conditions:   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Precancerous Condition;   Secondary Myelofibrosis
Interventions:   Drug: Busulfan;   Drug: Cytarabine;   Drug: Fludarabine phosphate;   Drug: mycophenolate mofetil;   Drug: tacrolimus;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: umbilical cord blood transplantation;   Radiation: total-body irradiation
Sponsors:   Barbara Ann Karmanos Cancer Institute;   Barbara Ann Karmanos Cancer Institute;   National Cancer Institute (NCI)
Recruiting - verified October 2011

Conditions:   Graft Versus Host Disease;   Leukemia;   Myelodysplastic Syndromes
Interventions:   Biological: filgrastim;   Drug: clofarabine;   Drug: melphalan;   Drug: mycophenolate mofetil;   Drug: tacrolimus;   Drug: thiotepa;   Procedure: allogeneic bone marrow transplantation;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation
Sponsors:   National Cancer Institute (NCI);   Memorial Sloan-Kettering Cancer Center;   National Cancer Institute (NCI)
Recruiting - verified January 2011

Conditions:   Chronic Myeloproliferative Disorders;   Graft Versus Host Disease;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Neoplasms;   Secondary Myelofibrosis;   Small Intestine Cancer
Interventions:   Biological: therapeutic allogeneic lymphocytes;   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: fludarabine phosphate;   Drug: tacrolimus;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: in vitro-treated peripheral blood stem cell transplantation;   Procedure: peripheral blood stem cell transplantation;   Radiation: total-body irradiation
Sponsors:   National Cancer Institute (NCI);   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified June 2009

Condition:   Lichen Sclerosus
Intervention:   Drug: pimecrolimus and clobetasol
Sponsors:   Center for Vulvovaginal Disorders;   Center for Vulvovaginal Disorders;   Novartis
Recruiting - verified October 2006

Conditions:   Graft Versus Host Disease;   Leukemia
Interventions:   Drug: methotrexate;   Drug: sirolimus;   Drug: tacrolimus
Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified April 2011

Condition:   Paraneoplastic Syndromes
Intervention:   Drug: Tacrolimus (FK506)
Sponsors:   Rockefeller University;   Rockefeller University
Recruiting - verified January 2012

Condition:   Nonneoplastic Condition
Interventions:   Drug: cyclophosphamide;   Radiation: total-body irradiation;   Drug: fludarabine phosphate;   Drug: mycophenolate mofetil;   Drug: tacrolimus;   Procedure: allogeneic bone marrow transplantation;   Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation;   Other: laboratory biomarker analysis
Sponsors:   Fred Hutchinson Cancer Research Center;   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI);   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified January 2012

Conditions:   Graft vs Host Disease;   Blood and Marrow Transplant (BMT)
Interventions:   Drug: Rituximab;   Drug: Prednisone;   Drug: cyclosporine A;   Drug: tacrolimus
Sponsors:   Stanford University;   Stanford University
Recruiting - verified August 2011

Conditions:   Multiple Myeloma;   Lymphoma;   Acute Myelogenous Leukemia;   Acute Lymphocytic Leukemia;   Myelodysplastic Syndrome
Intervention:   Drug: Tacrolimus and MMF
Sponsors:   Rocky Mountain Blood and Marrow Transplant Program;   Rocky Mountain Blood and Marrow Transplant Program
Recruiting - verified March 2004

Conditions:   Kidney Transplant;   Diabetes Mellitus, Type 2;   Diabetic Nephropathy
Interventions:   Drug: Cyclosporin;   Drug: Tacrolimus;   Behavioral: Diabetes Education / Management
Sponsors:   Stanford University;   Stanford University
Recruiting - verified January 2007

Condition:   Diabetes Mellitus
Intervention:  
Sponsors:   University of Minnesota - Clinical and Translational Science Institute;   Michael Mauer, MD;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK);   National Institutes of Health (NIH)
Recruiting - verified April 2012

Condition:   Diabetes Mellitus, Type 1
Interventions:   Drug: Allogenic islet cells (human, U. Chicago);   Procedure: Intraportal infusion of islet cells
Sponsors:   University of Chicago;   University of Chicago
Recruiting - verified October 2010

Conditions:   Accelerated Phase Chronic Myelogenous Leukemia;   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   Blastic Phase Chronic Myelogenous Leukemia;   Burkitt Lymphoma;   Childhood Acute Lymphoblastic Leukemia in Remission;   Childhood Acute Myeloid Leukemia in Remission;   Childhood Chronic Myelogenous Leukemia;   Childhood Diffuse Large Cell Lymphoma;   Childhood Immunoblastic Large Cell Lymphoma;   Childhood Myelodysplastic Syndromes;   Childhood Nasal Type Extranodal NK/T-cell Lymphoma;   Chronic Eosinophilic Leukemia;   Chronic Neutrophilic Leukemia;   Chronic Phase Chronic Myelogenous Leukemia;   Contiguous Stage II Adult Burkitt Lymphoma;   Contiguous Stage II Adult Diffuse Large Cell Lymphoma;   Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma;   Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma;   Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma;   Contiguous Stage II Adult Lymphoblastic Lymphoma;   Contiguous Stage II Grade 1 Follicular Lymphoma;   Contiguous Stage II Grade 2 Follicular Lymphoma;   Contiguous Stage II Grade 3 Follicular Lymphoma;   Contiguous Stage II Mantle Cell Lymphoma;   Contiguous Stage II Marginal Zone Lymphoma;   Contiguous Stage II Small Lymphocytic Lymphoma;   Cutaneous B-cell Non-Hodgkin Lymphoma;   de Novo Myelodysplastic Syndromes;   Essential Thrombocythemia;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Hepatosplenic T-cell Lymphoma;   Intraocular Lymphoma;   Nodal Marginal Zone B-cell Lymphoma;   Noncontiguous Stage II Adult Burkitt Lymphoma;   Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma;   Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma;   Noncontiguous Stage II Adult Lymphoblastic Lymphoma;   Noncontiguous Stage II Grade 1 Follicular Lymphoma;   Noncontiguous Stage II Grade 2 Follicular Lymphoma;   Noncontiguous Stage II Grade 3 Follicular Lymphoma;   Noncontiguous Stage II Mantle Cell Lymphoma;   Noncontiguous Stage II Marginal Zone Lymphoma;   Noncontiguous Stage II Small Lymphocytic Lymphoma;   Peripheral T-cell Lymphoma;   Polycythemia Vera;   Post-transplant Lymphoproliferative Disorder;   Previously Treated Myelodysplastic Syndromes;   Primary Myelofibrosis;   Prolymphocytic Leukemia;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Adult T-cell Leukemia/Lymphoma;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Recurrent Childhood Anaplastic Large Cell Lymphoma;   Recurrent Childhood Grade III Lymphomatoid Granulomatosis;   Recurrent Childhood Large Cell Lymphoma;   Recurrent Childhood Lymphoblastic Lymphoma;   Recurrent Childhood Small Noncleaved Cell Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Recurrent/Refractory Childhood Hodgkin Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Multiple Myeloma;   Relapsing Chronic Myelogenous Leukemia;   Secondary Myelodysplastic Syndromes;   Small Intestine Lymphoma;   Splenic Marginal Zone Lymphoma;   Stage I Adult Burkitt Lymphoma;   Stage I Adult Diffuse Large Cell Lymphoma;   Stage I Adult Diffuse Mixed Cell Lymphoma;   Stage I Adult Diffuse Small Cleaved Cell Lymphoma;   Stage I Adult Immunoblastic Large Cell Lymphoma;   Stage I Adult Lymphoblastic Lymphoma;   Stage I Adult T-cell Leukemia/Lymphoma;   Stage I Childhood Anaplastic Large Cell Lymphoma;   Stage I Childhood Large Cell Lymphoma;   Stage I Childhood Lymphoblastic Lymphoma;   Stage I Chronic Lymphocytic Leukemia;   Stage I Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage I Grade 1 Follicular Lymphoma;   Stage I Grade 2 Follicular Lymphoma;   Stage I Grade 3 Follicular Lymphoma;   Stage I Mantle Cell Lymphoma;   Stage I Marginal Zone Lymphoma;   Stage I Multiple Myeloma;   Stage I Mycosis Fungoides/Sezary Syndrome;   Stage I Small Lymphocytic Lymphoma;   Stage II Adult T-cell Leukemia/Lymphoma;   Stage II Childhood Anaplastic Large Cell Lymphoma;   Stage II Childhood Large Cell Lymphoma;   Stage II Childhood Lymphoblastic Lymphoma;   Stage II Chronic Lymphocytic Leukemia;   Stage II Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage II Multiple Myeloma;   Stage II Mycosis Fungoides/Sezary Syndrome;   Stage III Adult Burkitt Lymphoma;   Stage III Adult Diffuse Large Cell Lymphoma;   Stage III Adult Diffuse Small Cleaved Cell Lymphoma;   Stage III Adult Immunoblastic Large Cell Lymphoma;   Stage III Adult Lymphoblastic Lymphoma;   Stage III Adult T-cell Leukemia/Lymphoma;   Stage III Childhood Anaplastic Large Cell Lymphoma;   Stage III Childhood Large Cell Lymphoma;   Stage III Childhood Lymphoblastic Lymphoma;   Stage III Chronic Lymphocytic Leukemia;   Stage III Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage III Grade 1 Follicular Lymphoma;   Stage III Grade 2 Follicular Lymphoma;   Stage III Grade 3 Follicular Lymphoma;   Stage III Mantle Cell Lymphoma;   Stage III Marginal Zone Lymphoma;   Stage III Multiple Myeloma;   Stage III Mycosis Fungoides/Sezary Syndrome;   Stage III Small Lymphocytic Lymphoma;   Stage IV Adult Burkitt Lymphoma;   Stage IV Adult Diffuse Large Cell Lymphoma;   Stage IV Adult Diffuse Mixed Cell Lymphoma;   Stage IV Adult Diffuse Small Cleaved Cell Lymphoma;   Stage IV Adult Immunoblastic Large Cell Lymphoma;   Stage IV Adult Lymphoblastic Lymphoma;   Stage IV Adult T-cell Leukemia/Lymphoma;   Stage IV Childhood Anaplastic Large Cell Lymphoma;   Stage IV Childhood Large Cell Lymphoma;   Stage IV Childhood Lymphoblastic Lymphoma;   Stage IV Chronic Lymphocytic Leukemia;   Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage IV Grade 1 Follicular Lymphoma;   Stage IV Grade 2 Follicular Lymphoma;   Stage IV Grade 3 Follicular Lymphoma;   Stage IV Mantle Cell Lymphoma;   Stage IV Marginal Zone Lymphoma;   Stage IV Mycosis Fungoides/Sezary Syndrome;   Stage IV Small Lymphocytic Lymphoma;   Testicular Lymphoma;   Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Adult Acute Myeloid Leukemia;   Untreated Childhood Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies;   Waldenstrom Macroglobulinemia
Interventions:   Drug: fludarabine phosphate;   Radiation: total-body irradiation;   Drug: mycophenolate mofetil;   Drug: tacrolimus;   Procedure: bone marrow aspiration;   Procedure: peripheral blood stem cell transplantation;   Genetic: polymerase chain reaction;   Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation;   Other: immunologic technique;   Other: laboratory biomarker analysis
Sponsors:   Fred Hutchinson Cancer Research Center;   Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium;   National Heart, Lung, and Blood Institute (NHLBI);   National Cancer Institute (NCI)
Recruiting - verified April 2012

Condition:   Leukemia
Interventions:   Biological: filgrastim;   Biological: graft-versus-tumor induction therapy;   Drug: busulfan;   Drug: fludarabine phosphate;   Drug: methotrexate;   Drug: tacrolimus;   Procedure: peripheral blood stem cell transplantation
Sponsors:   National Cancer Institute (NCI);   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
Recruiting - verified April 2011